DDInter1851 DDInter927
Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression. A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and SNRI therapy. Trazodone acts on various receptors, including certain histamine, serotonin, and adrenergic receptors, distinguishing it from other antidepressants that cover a narrow range of neurotransmitters. It was initially granted FDA approval in 1981.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Trazodone {u} (Compound) resembles {v} (Compound) Zuclopenthixol
Trazodone {u} (Compound) resembles {v} (Compound) Quetiapine
Trazodone {u} (Compound) binds {v} (Gene) HTR2C
Trazodone {u} (Compound) palliates {v} (Disease) bipolar disorder
Trazodone {u} (Compound) downregulates {v} (Gene) PIN1
Trazodone {u} (Compound) causes {v} (Side Effect) Tachycardia
Trazodone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Trazodone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Levothyroxine
Trazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Trazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinine
Trazodone (Compound) resembles Zuclopenthixol (Compound)
Trazodone (Compound) resembles Quetiapine (Compound)
Trazodone (Compound) binds HTR2C (Gene)
Trazodone (Compound) palliates bipolar disorder (Disease)
Trazodone (Compound) downregulates PIN1 (Gene)
Trazodone (Compound) causes Tachycardia (Side Effect)
Trazodone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Trazodone may cause a minor interaction that can limit clinical effects when taken with Levothyroxine
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Quinine